Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer

NCT00146562 is registered in ClinicalTrials.gov with Harold J. Burstein, MD, PhD as lead sponsor.

NCT NCT00146562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Lead sponsor
Harold J. Burstein, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
May 31, 2007
Enrollment
135 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, stage i breast cancer, stage ii breast cancer